🚀 VC round data is live in beta, check it out!
FibroGen Valuation Multiples
Discover revenue and EBITDA valuation multiples for FibroGen and similar public comparables like Outlook Therapeutics, Generation Bio, Mabion, PDS Biotechnology and more.
FibroGen Overview
Founded
N/A
HQ
—
Employees
225
Website
N/A
Sectors
Financials (LTM)
EV
$87M
FibroGen Financials
FibroGen reported last 12-month revenue of $7M and negative EBITDA of ($46M).
In the same LTM period, FibroGen generated $6M in gross profit, ($46M) in EBITDA losses, and had net loss of ($47M).
Revenue (LTM)
FibroGen P&L
In the most recent fiscal year, FibroGen reported revenue of — and net income of —.
FibroGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $6M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($46M) | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (687%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (694%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($47M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (711%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
FibroGen Stock Performance
FibroGen has current market cap of $36M, and enterprise value of $87M.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $87M | $36M | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFibroGen Valuation Multiples
FibroGen trades at 13.1x EV/Revenue multiple, and (1.9x) EV/EBITDA.
FibroGen Financial Valuation Multiples
As of March 7, 2026, FibroGen has market cap of $36M and EV of $87M.
Equity research analysts estimate FibroGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
FibroGen has a P/E ratio of (0.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36M | XXX | $36M | XXX | XXX | XXX |
| EV (current) | $87M | XXX | $87M | XXX | XXX | XXX |
| EV/Revenue | 13.1x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (1.9x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (1.9x) | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 13.8x | XXX | — | XXX | XXX | XXX |
| P/E | (0.8x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified FibroGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
FibroGen Margins & Growth Rates
FibroGen's revenue in the last 12 month declined by (8%).
FibroGen's revenue per employee in the last FY averaged $0.0M.
FibroGen's rule of 40 is (695%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
FibroGen's rule of X is (707%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
FibroGen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (8%) | XXX | (77%) | XXX | XXX | XXX |
| EBITDA Margin | (687%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | (29%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (695%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (707%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 428% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 350% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
FibroGen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Outlook Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Generation Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| PDS Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
FibroGen M&A Activity
FibroGen acquired XXX companies to date.
Last acquisition by FibroGen was on XXXXXXXX, XXXXX. FibroGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by FibroGen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFibroGen Investment Activity
FibroGen invested in XXX companies to date.
FibroGen made its latest investment on XXXXXXXX, XXXXX. FibroGen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by FibroGen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout FibroGen
| How many employees does FibroGen have? | As of today, FibroGen has over 225 employees. |
| Is FibroGen publicly listed? | Yes, FibroGen is a public company listed on Nasdaq. |
| What is the stock symbol of FibroGen? | FibroGen trades under FGEN ticker. |
| When did FibroGen go public? | FibroGen went public in 2014. |
| Who are competitors of FibroGen? | FibroGen main competitors are Outlook Therapeutics, Generation Bio, Mabion, PDS Biotechnology. |
| What is the current market cap of FibroGen? | FibroGen's current market cap is $36M. |
| What is the current revenue of FibroGen? | FibroGen's last 12 months revenue is $7M. |
| What is the current revenue growth of FibroGen? | FibroGen revenue growth (NTM/LTM) is (8%). |
| What is the current EV/Revenue multiple of FibroGen? | Current revenue multiple of FibroGen is 13.1x. |
| Is FibroGen profitable? | No, FibroGen is not profitable. |
| What is the current EBITDA of FibroGen? | FibroGen has negative EBITDA and is not profitable. |
| What is FibroGen's EBITDA margin? | FibroGen's last 12 months EBITDA margin is (687%). |
| What is the current EV/EBITDA multiple of FibroGen? | Current EBITDA multiple of FibroGen is (1.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.